^
Association details:
| Biomarker: | HAVCR2 expression |
|---|---|
| Cancer: | Nasopharyngeal Carcinoma |
| Drug: | spartalizumab (PDR001) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, Versus Chemotherapy in Patients With Recurrent/Metastatic Nasopharyngeal Cancer
Published date:
08/25/2021
Excerpt:
Median duration of response (DOR) was 10.2 versus 5.7 months in spartalizumab versus chemotherapy arms, respectively. Median overall survival (OS) was 25.2 and 15.5 months in spartalizumab and chemotherapy arms, respectively. Tumor RNA sequencing showed a correlation between response to spartalizumab and IFN-γ, LAG-3, and TIM-3 gene expression.
DOI:
10.1158/1078-0432.CCR-21-0822
Trial ID:
